The expiry of the semaglutide patent in India in March 2026 has led to a major shift in access to GLP-1 receptor agonist therapies. These drugs, widely used for type 2 diabetes and obesity, are now being produced by multiple Indian pharmaceutical companies in generic form.
More than 40–50 manufacturers are expected to enter the market, significantly reducing costs and expanding availability across a larger patient population.
This change is likely to increase the use of GLP-1 drugs therapies beyond specialist endocrinology practice and into broader clinical settings.
Understanding GLP-1 Drugs and Its Systemic Effects
GLP-1 receptor agonists, including semaglutide, mimic a natural hormone that regulates blood sugar. They increase insulin secretion, reduce glucagon levels, slow gastric emptying, and suppress appetite.
These mechanisms result in:
- Improved glycaemic control
- Sustained weight loss
- Reduced cardiovascular risk in selected populations
Because of these combined effects, GLP-1 drugs are now considered a key component in managing metabolic disease.
The Link Between Obesity and Sinus Disease
Obesity is not only a metabolic condition. It is associated with chronic low-grade inflammation.
This inflammatory state has been linked to:
- Chronic rhinosinusitis
- Impaired mucociliary clearance
- Increased susceptibility to upper respiratory infections
Inflammation in obesity affects multiple systems, including the airway. This is relevant in ENT practice, where many patients with chronic sinus symptoms also have underlying metabolic dysfunction.
Potential Impact of GLP-1 Therapy on Airway Health
With increasing use of GLP-1 therapies, there is growing interest in their broader effects on inflammation.
Studies have shown that GLP-1 receptor agonists can:
- Reduce systemic inflammatory markers
- Improve metabolic parameters associated with inflammation
- Lower risk of major cardiovascular events by up to 20% in high-risk patients
Given the role of inflammation in sinus disease, this raises an important question: can metabolic control indirectly improve airway health?
While direct evidence specific to chronic sinusitis is still limited, the systemic anti-inflammatory effects of GLP-1 therapies suggest a potential benefit in selected patients.
Clinical Observations: ENT Symptoms in GLP-1 Users
As usage increases, clinicians are also seeing patients on GLP-1 therapy presenting with upper airway symptoms.
Common complaints include:
- Nasal congestion
- Throat irritation
- Postnasal drip
These symptoms are often not due to primary sinus infection. Instead, they may be related to:
- Gastroesophageal reflux, which can be influenced by delayed gastric emptying
- Mucosal sensitivity changes
- Medication-related physiological effects
This distinction is important to avoid unnecessary antibiotic use or misdiagnosis.
Access, Affordability, and Clinical Responsibility
The introduction of generic semaglutide has made these therapies more accessible. Prices are expected to drop significantly, in some cases by up to 50–90%, depending on the formulation and manufacturer.
This increased access brings both opportunity and responsibility.
From a clinical perspective, it is important to focus on:
- Appropriate patient selection
- Clear indications for use
- Monitoring for systemic and airway-related effects
GLP-1 therapies are not a replacement for standard ENT management but may influence disease patterns in patients with metabolic comorbidities.
Conclusion
GLP-1 receptor agonists are becoming part of routine clinical care in India due to improved affordability and availability.
Their role extends beyond glucose control and weight loss. By influencing systemic inflammation, they may indirectly affect airway and sinus health.
At the same time, new symptom patterns are emerging that require careful evaluation.
As these therapies become more widely used, a multidisciplinary approach involving endocrinology and ENT practice will be important to ensure appropriate use and optimal patient outcomes.
FAQs
What are GLP-1 receptor agonists and how do they work?
GLP-1 receptor agonists are medications that mimic a natural hormone to regulate blood sugar. They improve insulin secretion, reduce appetite, and support weight loss.
Are GLP-1 drugs like semaglutide now available in India as generics?
Yes, after the patent expiry of semaglutide in March 2026, multiple Indian manufacturers are producing more affordable generic versions.
Can obesity worsen sinus and airway conditions?
Yes, obesity is linked to chronic inflammation, which can contribute to conditions like chronic rhinosinusitis and impaired airway function.
Do GLP-1 drugs help improve sinus health?
While direct evidence is limited, GLP-1 drugs reduce systemic inflammation, which may indirectly benefit sinus and airway health in some patients.
What ENT symptoms are seen in patients using GLP-1 therapy?
Some patients may experience nasal congestion, throat irritation, and postnasal drip, often related to reflux or medication effects rather than infection.
Should GLP-1 medications replace ENT treatments for sinus issues?
No, GLP-1 therapies do not replace ENT treatments. They may complement overall health management but require proper evaluation and monitoring.